Jan 19 2009
Roxane Laboratories, Inc. has announced the approval of their Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250mg, 500mg, 750mg, 1000mg, and Oral Solution 100mg/mL.
The product is available for immediate shipment to wholesalers and pharmacies nationwide.
Roxane Laboratories' Levetiracetam Tablets and Oral Solution are AB rated to UCB, Inc.'s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) Tablets and Oral Solution are approximately $1.28 Billion (1).
Full prescribing information for Levetiracetam Tablets and Oral Solution is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.